
the risk of death and nonfatal cardiac events in patients with
left ventricular dysfunction.78,79 In the Heart Outcomes
Prevention Evaluation study, 4051 patients with PAD treated
with ramipril had a 25% reduction of cardiac events.80 This is
notable, particularly in the context of a recent trial examining
the effects of ramipril on walking performance (Section 4B).
Antiplatelet and antithrom